reconstitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
=== Viscosity === The rheology of nanocellulose dispersions has been investigated. and revealed that the storage and loss modulus were independent of the angular frequency at all nanocellulose concentrations between 0.125% to 5.9%. The storage modulus values are particularly high (104 Pa at 3% concentration) compared to results for CNCs (102 Pa at 3% concentration). There is also a strong concentration dependence as the storage modulus increases 5 orders of magnitude if the concentration is increased from 0.125% to 5.9%. Nanocellulose gels are also highly shear thinning (the viscosity is lost upon introduction of the shear forces). The shear-thinning behaviour is particularly useful in a range of different coating applications. It is pseudo-plastic and exhibits thixotropy, the property of certain gels or fluids that are thick (viscous) under normal conditions, but become less viscous when shaken or agitated. When the shearing forces are removed the gel regains much of its original state.
EC 2.4.2.24: 1,4-β-D-xylan synthase EC 2.4.2.25: flavone apiosyltransferase EC 2.4.2.26: protein xylosyltransferase EC 2.4.2.27: dTDP-dihydrostreptose—streptidine-6-phosphate dihydrostreptosyltransferase EC 2.4.2.28: S-methyl-5′-thioadenosine phosphorylase EC 2.4.2.29: tRNA-guanosine34 preQ1 transglycosylase EC 2.4.2.30: NAD+ ADP-ribosyltransferase EC 2.4.2.31: NAD+—protein-arginine ADP-ribosyltransferase EC 2.4.2.32: dolichyl-phosphate D-xylosyltransferase EC 2.4.2.33: dolichyl-xylosyl-phosphate—protein xylosyltransferase EC 2.4.2.34: indolylacetylinositol arabinosyltransferase EC 2.4.2.35: flavonol-3-O-glycoside xylosyltransferase EC 2.4.2.36: NAD+—diphthamide ADP-ribosyltransferase EC 2.4.2.37: NAD+ —dinitrogen-reductase ADP-D-ribosyltransferase EC 2.4.2.38: glycoprotein 2-β-D-xylosyltransferase EC 2.4.2.39: xyloglucan 6-xylosyltransferase EC 2.4.2.40: zeatin O-β-D-xylosyltransferase EC 2.4.2.41: xylogalacturonan β-1,3-xylosyltransferase EC 2.4.2.42: UDP-D-xylose:β-D-glucoside α-1,3-D-xylosyltransferase EC 2.4.2.43: lipid IVA 4-amino-4-deoxy-L-arabinosyltransferase EC 2.4.2.44: S-methyl-5′-thioinosine phosphorylase EC 2.4.2.45: decaprenyl-phosphate phosphoribosyltransferase EC 2.4.2.46: galactan 5-O-arabinofuranosyltransferase EC 2.4.2.47: arabinofuranan 3-O-arabinosyltransferase EC 2.4.2.48: tRNA-guanine15 transglycosylase EC 2.4.2.49: neamine phosphoribosyltransferase EC 2.4.2.50: cyanidin 3-O-galactoside 2′′-O-xylosyltransferase EC 2.4.2.51: anthocyanidin 3-O-glucoside 2′′′-O-xylosyltransferase EC 2.4.2.52: triphosphoribosyl-dephospho-CoA synthase EC 2.4.2.53: undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase EC 2.4.2.54: β-ribofuranosylphenol 5′-phosphate synthase EC 2.4.2.55: nicotinate D-ribonucleotide:phenol phospho-D-ribosyltransferase EC 2.4.2.56: kaempferol 3-O-xylosyltransferase EC 2.4.2.57: AMP phosphorylase EC 2.4.2.58: hydroxyproline O-arabinosyltransferase EC 2.4.2.59: sulfide-dependent adenosine diphosphate thiazole synthase EC 2.4.2.60: cysteine-dependent adenosine diphosphate thiazole synthase EC 2.4.2.61: α-dystroglycan β1,4-xylosyltransferase EC 2.4.2.62: xylosyl α-1,3-xylosyltransferase EC 2.4.2.63: EGF-domain serine xylosyltransferase EC 2.4.2.64: tRNA-guanosine34 queuine transglycosylase
The season premiered on the streaming service Amazon Prime Video on June 3, 2022, with its first three episodes. The remaining five episodes were released weekly until July 8, 2022. The season received critical acclaim with praise towards its action sequences, social commentary, visual effects, character development, story, and performances (particularly Urban, Quaid, Starr, McElligott, Alonso, and Ackles). This season is widely regarded as the best season of the show. It received multiple nominations including two Primetime Creative Arts Emmy Awards, earning one for stunt coordination. On June 10, 2022, the series was renewed for a fourth season.
==== Antitumorigenic activities ==== Honokiol has shown pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma, in glioblastome multiforme cells and colon cancer cell lines. Honokiol inhibits phosphorylation of Akt, p44/42 mitogen-activated protein kinase (MAPK), and src. Additionally, honokiol regulates the nuclear factor kappa B (NF-κB) activation pathway, an upstream effector of vascular endothelial growth factor (VEGF), MCL1, and cyclooxygenase 2 (COX-2), all significant pro-angiogenic and survival factors. Honokiol induces caspase-dependent apoptosis in a TRAIL-mediated manner, and potentiates the pro-apoptotic effects of doxorubicin and other etoposides. So potent is honokiol's pro-apoptotic effects that it overcomes even notoriously drug resistant neoplasms such as multiple myeloma and chronic B-cell leukemia. Honokiol also acts on the PI3K/mTOR pathway in tumor cells while maintaining pathway activity in T cells.
=== Source, Steam, and Half-Life 2 (2003–2010) === In 2003, Valve moved to Bellevue, Washington, and reincorporated as Valve Corporation. In 2010, the office moved to a larger location in Bellevue. In 2016, Valve signed a nine-floor lease in the Lincoln Square complex in downtown Bellevue, doubling the size of its offices. Valve began developing Half-Life 2 six months after the release of the first Half-Life, using its new in-house engine, Source. With advanced physics systems and an increased focus on story and characters, it received critical acclaim upon its release in 2004. By 2011, it had sold 12 million copies. In 2002, Valve launched Steam, a digital storefront and delivery platform. Steam initially offered only Valve games, and was mandatory to install Half-Life 2, but it later became a publisher of third-party games. As Valve became its own publisher via Steam, it transitioned to a flat organization. Outside of executive management, Valve does not have bosses and uses an open allocation system, allowing employees to move between departments at will. In July 2005, Electronic Arts was announced to partner with Valve for a multi-year game distribution agreement, following Vivendi Universal's promise to end distribution on August 31. After having taken five years to develop Half-Life 2, Valve moved to episodic development, planning to release shorter games more frequently. Half-Life 2: Episode One, the first in a planned trilogy of episodic Half-Life 2 sequels, was released in 2006.
Sources: en.wikipedia.org
=== Blood cultures === Blood cultures can allow for diagnostic results after culture. Recent development of DNA based PCR diagnostics have provided faster diagnostic results as opposed to overnight biochemical tests. DNA diagnostic test can diagnose with near the same specificity as biochemical test, resulting in the same diagnostic result in 90% of cases.
For example, efavirenz and nelfinavir are two types of drugs that help decrease the HIV infection in a person's body. When the SNP from exon 26 is coupled with other SNP exons, the drugs have a lower chance of maintaining the HIV infection. Although, when the TT nucleotides in exon 26 are expressed the patient has a lower concentration of the virus but when the genotype morphs into CC or CT the infection is able to spread like normal leaving the MDR 1 gene almost defenseless. These changes in bases of exon 26 for MDR 1 show a correlation between the MDR 1 gene mutations and the ability of the antiretroviral drugs to suppress the HIV infection. Exon 26 has also been studied as to whether it is haplotype dependent or not. The presence of the SNP of exon 26 changes phenotypic functions when it is paired with the presence of mutations from exons 12 and 21. But when acting alone, it does not affect the phenotypic outcome as strongly. An example of exon 26's haplotype dependency is seen when looking at chemotherapy. Since MDR 1 removes drugs from our cells, inhibitors have been used to block MRD 1's ability to remove drugs, thus letting beneficial drugs like chemotherapy and immunosuppressants aid the body in recovery more efficiently. MDR1 has different proteins that help exile these specific drugs from cancer cells. Verapamil and cyclosporine A are common inhibitors for MDR 1.
=== Koornhof Bills === The key national political development in the run-up to the uprising was the introduction of a package of political reforms by the South African government, then led by P. W. Botha. The government proposed that it would maintain the system of racial separation known as apartheid while also providing for increased political representation of non-white groups. A new Constitution and a package of three laws – known as the Koornhof Bills after Minister Piet Koornhof – would achieve this by establishing a Tricameral Parliament, with separate junior houses for Coloureds and Indians respectively, and by expanding the powers of community councils in black townships, henceforth known as black local authorities. Because these reforms provided only superficial political representation for non-whites, they were vociferously opposed by most of the anti-apartheid movement. The first elections to black local authorities took place in late 1983 with very poor turnout; and the first elections to the Tricameral Parliament in 1984 were marred by a successful boycott campaign, spearheaded by the United Democratic Front (UDF) and its affiliates.
Alogliptin (Figure 9) is a novel DPP-4 inhibitor developed by the Takeda Pharmaceutical Company. Researchers hypothesized that a quinazolinone based structure (Figure 9) would have the necessary groups to interact with the active site on the DPP-4 complex. Quinazolinone based compounds interacted effectively with the DPP-4 complex, but suffered from low metabolic half-life. It was found that when replacing the quinazolinone with a pyrimidinedione, the metabolic stability was increased and the result was a potent, selective, bioavailable DPP-4 inhibitor named alogliptin. The quinazoline based compounds showed potent inhibition and excellent selectivity over related protease, DPP-8. However, short metabolic half-life due to oxidation of the A-ring phenyl group was problematic. At first, the researchers tried to make a fluorinated derivative. The derivative showed improved metabolic stability and excellent inhibition of the DPP-4 enzyme. However, it was also found to inhibit CYP 450 3A4 and block the hERG channel. The solution to this problem was to replace the quinazolinone with other heterocycles, but the quinazolinone could be replaced without any loss of DPP-4 inhibition. Alogliptin was discovered when quinazolinone was replaced with a pyrimidinedione. Alogliptin has shown excellent inhibition of DPP-4 and extraordinary selectivity, greater than 10.000 fold over the closely related serine proteases DPP-8 and DPP-9. Also, it does not inhibit the CYP 450 enzymes nor block the hERG channel at concentration up to 30 μM.
Meso-zeaxanthin (3R,3′S-zeaxanthin) is a xanthophyll carotenoid, and is one of the three stereoisomers of zeaxanthin. The meso- form is the second most abundant in nature, after 3R,3′R-zeaxanthin, which is produced by plants and algae. Meso-zeaxanthin has been identified in specific tissues of marine organisms and in the macula lutea, also known as the "yellow spot" of the human retina.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.